Skip to main content
Bone Density in Children With Chronic Liver Disease Correlates With Growth and Cholestasis.
Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.
Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection.
The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.
Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis.
Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease.
Five-year histological and serological follow-up of operationally tolerant pediatric liver transplant recipients enrolled in WISP-R.
Liver capsule: Age-influenced hepatic immune priming determines HBV infection fate: Implications from mouse to man.
Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B.
Treatment of bile acid amidation defects with glycocholic acid.